A share price of Autolus Therapeutics plc ADR [AUTL] is currently trading at $1.37, down -1.44%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AUTL shares have gain 7.87% over the last week, with a monthly amount drifted -11.04%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Autolus Therapeutics plc ADR [NASDAQ: AUTL] stock has seen the most recent analyst activity on November 18, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $7.60 from $7. Previously, Redburn Atlantic upgraded its rating to Buy on November 15, 2024, and kept the price target unchanged to $13. On November 09, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $10 on the stock. Bryan Garnier initiated its recommendation with a Buy and recommended $5 as its price target on March 17, 2023. Jefferies upgraded its rating to Buy for this stock on June 14, 2021, and upped its price target to $12. In a note dated January 29, 2021, JP Morgan downgraded a Neutral rating on this stock but restated the target price of $9.
Autolus Therapeutics plc ADR experienced fluctuations in its stock price throughout the past year between $1.11 and $3.45. Currently, Wall Street analysts expect the stock to reach $8.87 within the next 12 months. Autolus Therapeutics plc ADR [NASDAQ: AUTL] shares were valued at $1.37 at the most recent close of the market. An investor can expect a potential return of 547.45% based on the average AUTL price forecast.
Analyzing the AUTL fundamentals
Gross Profit Margin for this corporation currently stands at -0.67% with Operating Profit Margin at -9.03%, Pretax Profit Margin comes in at -7.47%, and Net Profit Margin reading is -7.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.56 and Total Capital is -0.41. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3267 points at the first support level, and at 1.2833 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4067, and for the 2nd resistance point, it is at 1.4433.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Autolus Therapeutics plc ADR [NASDAQ:AUTL] is 6.15. Also, the Quick Ratio is 5.82, while the Cash Ratio stands at 1.82. Considering the valuation of this stock, the price to sales ratio is 7.11, the price to book ratio is 1.83.
